Skip to main content
. 2014 Apr 8;9:593–601. doi: 10.2147/CIA.S51940

Figure 1.

Figure 1

Mechanism of action of denosumab. High affinity binding of denosumab to RANKL inhibits osteoclast maturation, activity, and survival by preventing RANKL from binding the RANK receptor on immature and mature osteoclasts. This decreases bone resorption and suppresses bone turnover.

Abbreviations: RANKL, receptor activator of nuclear factor kappa-β ligand; RANK, receptor activator of nuclear factor kappa-β.